No Data
No Data
Hoth Therapeutics Achieves Breakthrough In Phase 2a HT-001 Trial Delivering 100% Success in Combating Cancer Treatment Skin Toxicities; 100% Of Patients In Cohort 1 Achieve Primary Efficacy Endpoint
Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment
Dow Surges Over 100 Points; US Trade Deficit Widens In November
Express News | Hoth Therapeutics Inc - Preserves Cancer Treatment Efficacy With Zero Dose Reductions
Express News | Hoth Therapeutics Inc - No Treatment-Related Adverse Effects Observed
Express News | Hoth Therapeutics Inc - 100% of Patients Achieve Primary Efficacy Endpoint